Aptevo Files Patent for Nectin-4 x PD-L1 Dual-Targeting Backbone
Aptevo Therapeutics Inc. announced a new solid tumor strategy and the filing of a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone. The company believes this technology will strengthen its oncology pipeline, support multiple therapeutic approaches from a single platform, and expand potential partnering opportunities. This versatile backbone is designed to be adapted for various cancer-fighting methods, including radiopharmaceuticals and T-cell engagers, by targeting Nectin-4 and PD-L1 in solid tumors.
Key Highlights
- Aptevo announced a new solid tumor strategy.
- Filed a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone.
- Technology designed to strengthen the oncology pipeline.
- Aims to support multiple therapeutic approaches from a single platform.
- Expected to expand potential partnering opportunities.
- Backbone can be adapted for radiopharmaceuticals, T-cell engagers, and other immune-based therapies.
- Targets Nectin-4 on solid tumors and PD-L1 on tumor cells and immune-suppressing cells.
Price Impact
More from APVO
Aptevo Therapeutics Extends Rights Agreement Expiration to Oct 2027, Adjusts Purchase Price
Aptevo Therapeutics Raises $4.5M via Warrant Exercise & PIPE
Aptevo Schedules 2026 Annual Meeting; Key Proposals Include Director Elections, Stock Plan